BRPI1012282A2 - inibidores de anel fundidos da hepatite c. - Google Patents
inibidores de anel fundidos da hepatite c.Info
- Publication number
- BRPI1012282A2 BRPI1012282A2 BRPI1012282A BRPI1012282A BRPI1012282A2 BR PI1012282 A2 BRPI1012282 A2 BR PI1012282A2 BR PI1012282 A BRPI1012282 A BR PI1012282A BR PI1012282 A BRPI1012282 A BR PI1012282A BR PI1012282 A2 BRPI1012282 A2 BR PI1012282A2
- Authority
- BR
- Brazil
- Prior art keywords
- hepatitis
- fused
- inhibitors
- ring
- ring inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16434209P | 2009-03-27 | 2009-03-27 | |
| US21488309P | 2009-04-28 | 2009-04-28 | |
| PCT/US2010/028730 WO2010111534A1 (en) | 2009-03-27 | 2010-03-25 | Fused ring inhibitors of hepatitis c |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI1012282A2 true BRPI1012282A2 (pt) | 2015-09-22 |
Family
ID=42781523
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI1012282A BRPI1012282A2 (pt) | 2009-03-27 | 2010-03-25 | inibidores de anel fundidos da hepatite c. |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US9150554B2 (enExample) |
| EP (1) | EP2410843A4 (enExample) |
| JP (1) | JP5735482B2 (enExample) |
| KR (1) | KR20110131312A (enExample) |
| CN (1) | CN102427726B (enExample) |
| AR (1) | AR076164A1 (enExample) |
| AU (1) | AU2010229795A1 (enExample) |
| BR (1) | BRPI1012282A2 (enExample) |
| CA (1) | CA2755658A1 (enExample) |
| CL (1) | CL2011002377A1 (enExample) |
| CO (1) | CO6450600A2 (enExample) |
| EA (1) | EA201190224A1 (enExample) |
| IL (1) | IL215202A0 (enExample) |
| MX (1) | MX2011010132A (enExample) |
| PE (1) | PE20120773A1 (enExample) |
| SG (1) | SG174883A1 (enExample) |
| TW (1) | TW201038560A (enExample) |
| WO (1) | WO2010111534A1 (enExample) |
| ZA (1) | ZA201107753B (enExample) |
Families Citing this family (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2740193A1 (en) | 2008-12-23 | 2010-07-01 | Abbott Laboratories | Anti-viral compounds |
| MX2011006333A (es) | 2008-12-23 | 2011-06-27 | Abbott Lab | Compuestos antivirales. |
| US8314135B2 (en) | 2009-02-09 | 2012-11-20 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole antivirals |
| US8394968B2 (en) | 2009-02-17 | 2013-03-12 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8242156B2 (en) | 2009-02-17 | 2012-08-14 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8188132B2 (en) | 2009-02-17 | 2012-05-29 | Enanta Pharmaceuticals, Inc. | Linked dibenzimidazole derivatives |
| US8673954B2 (en) | 2009-02-27 | 2014-03-18 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US9765087B2 (en) | 2009-02-27 | 2017-09-19 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8101643B2 (en) | 2009-02-27 | 2012-01-24 | Enanta Pharmaceuticals, Inc. | Benzimidazole derivatives |
| US8507522B2 (en) | 2009-03-06 | 2013-08-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20190127365A1 (en) | 2017-11-01 | 2019-05-02 | Merck Sharp & Dohme Corp. | Inhibitors of hepatitis c virus replication |
| EA020898B1 (ru) | 2009-03-27 | 2015-02-27 | Мерк Шарп Энд Домэ Корп. | Ингибиторы репликации вируса гепатита c |
| SG174883A1 (en) | 2009-03-27 | 2011-11-28 | Presidio Pharmaceuticals Inc | Fused ring inhibitors of hepatitis c |
| US8796466B2 (en) | 2009-03-30 | 2014-08-05 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| TW201038559A (en) | 2009-04-09 | 2010-11-01 | Bristol Myers Squibb Co | Hepatitis C virus inhibitors |
| US8143414B2 (en) | 2009-04-13 | 2012-03-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| MX2011010905A (es) | 2009-04-15 | 2011-11-01 | Abbott Lab | Compuestos antivirales. |
| US9139569B2 (en) * | 2009-05-12 | 2015-09-22 | Merck Sharp & Dohme Corp. | Fused tricyclic aryl compounds useful for the treatment of viral diseases |
| LT2873665T (lt) | 2009-05-13 | 2016-10-25 | Gilead Pharmasset Llc | Antivirusiniai junginiai |
| US8138215B2 (en) | 2009-05-29 | 2012-03-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8211928B2 (en) | 2009-05-29 | 2012-07-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US8937150B2 (en) | 2009-06-11 | 2015-01-20 | Abbvie Inc. | Anti-viral compounds |
| US9394279B2 (en) | 2009-06-11 | 2016-07-19 | Abbvie Inc. | Anti-viral compounds |
| US8716454B2 (en) | 2009-06-11 | 2014-05-06 | Abbvie Inc. | Solid compositions |
| RS52854B (sr) | 2009-06-11 | 2013-12-31 | Abbvie Bahamas Limited | Inhibitori hepatitis c virusa |
| US8221737B2 (en) | 2009-06-16 | 2012-07-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8609648B2 (en) | 2009-07-02 | 2013-12-17 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| CN102656160A (zh) | 2009-07-16 | 2012-09-05 | 顶点制药公司 | 用于治疗或预防黄病毒感染的苯并咪唑类似物 |
| HRP20171454T8 (hr) | 2009-07-27 | 2018-01-12 | Gilead Sciences, Inc. | Fuzionirani heterociklični spojevi kao modulatori ionskih kanala |
| CA2771327A1 (en) | 2009-09-04 | 2011-03-10 | Glaxosmithkline Llc | Chemical compounds |
| EP2475256A4 (en) | 2009-09-11 | 2013-06-05 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| US8759332B2 (en) | 2009-09-11 | 2014-06-24 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8703938B2 (en) | 2009-09-11 | 2014-04-22 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8815928B2 (en) | 2009-09-11 | 2014-08-26 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8822700B2 (en) | 2009-09-11 | 2014-09-02 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8927709B2 (en) | 2009-09-11 | 2015-01-06 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US20110269956A1 (en) | 2009-11-11 | 2011-11-03 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110274648A1 (en) | 2009-11-11 | 2011-11-10 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US20110281910A1 (en) | 2009-11-12 | 2011-11-17 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| US8653070B2 (en) | 2009-12-14 | 2014-02-18 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8377980B2 (en) | 2009-12-16 | 2013-02-19 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011075607A1 (en) * | 2009-12-18 | 2011-06-23 | Intermune, Inc. | Novel inhibitors of hepatitis c virus replication |
| US8362020B2 (en) | 2009-12-30 | 2013-01-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| PE20130244A1 (es) | 2010-01-25 | 2013-03-10 | Enanta Pharm Inc | Inhibidores del virus de la hepatitis c |
| US8933110B2 (en) | 2010-01-25 | 2015-01-13 | Enanta Pharmaceuticals, Inc. | Hepatitis C virus inhibitors |
| US8623814B2 (en) | 2010-02-23 | 2014-01-07 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| US8178531B2 (en) | 2010-02-23 | 2012-05-15 | Enanta Pharmaceuticals, Inc. | Antiviral agents |
| AU2010347272A1 (en) | 2010-03-04 | 2012-09-20 | Enanta Pharmaceuticals, Inc. | Combination pharmaceutical agents as inhibitors of HCV replication |
| AU2011232331A1 (en) | 2010-03-24 | 2012-10-11 | Vertex Pharmaceuticals Incorporated | Analogues for the treatment or prevention of Flavivirus infections |
| EP2555622A4 (en) | 2010-04-09 | 2013-09-18 | Enanta Pharm Inc | HEPATITIS C-VIRUS HEMMER |
| WO2011153396A1 (en) | 2010-06-04 | 2011-12-08 | Enanta Pharmaceuticals, Inc | Hepatitis c virus inhibitors |
| NZ605440A (en) | 2010-06-10 | 2014-05-30 | Abbvie Bahamas Ltd | Solid compositions comprising an hcv inhibitor |
| NZ604478A (en) | 2010-07-02 | 2014-12-24 | Gilead Sciences Inc | Fused heterocyclic compounds as ion channel modulators |
| WO2012003642A1 (en) * | 2010-07-09 | 2012-01-12 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds and use thereof for treating viral diseases |
| CA2805440A1 (en) * | 2010-07-26 | 2012-02-09 | Merck Sharp & Dohme Corp. | Substituted biphenylene compounds and methods of use thereof for the treatment of viral diseases |
| WO2012021704A1 (en) | 2010-08-12 | 2012-02-16 | Enanta Pharmaceuticals, Inc. | Hepatitis c virus inhibitors |
| WO2012050918A2 (en) | 2010-09-29 | 2012-04-19 | Presidio Pharmaceutical, Inc. | Tricyclic fused ring inhibitors of hepatitis c |
| CA2812779A1 (en) | 2010-09-29 | 2012-04-19 | Merck Sharp & Dohme Corp. | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| SI2640719T1 (sl) | 2010-11-17 | 2017-07-31 | Gilead Pharmasset Llc | Antivirusne spojine |
| RU2452735C1 (ru) | 2010-11-30 | 2012-06-10 | Александр Васильевич Иващенко | Замещенные азолы, противовирусный активный компонент, фармацевтическая композиция, способ получения и применения |
| US8552047B2 (en) | 2011-02-07 | 2013-10-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2012122716A1 (en) | 2011-03-17 | 2012-09-20 | Merck Sharp & Dohme Corp. | Tetracyclic xanthene derivatives and methods of use thereof for treatment of viral diseases |
| CA2834164A1 (en) | 2011-05-10 | 2012-11-15 | Gilead Sciences, Inc. | Fused benzoxazinones as ion channel modulators |
| US9546160B2 (en) | 2011-05-12 | 2017-01-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US10201584B1 (en) | 2011-05-17 | 2019-02-12 | Abbvie Inc. | Compositions and methods for treating HCV |
| WO2012158861A2 (en) | 2011-05-18 | 2012-11-22 | Enanta Pharmaceuticals, Inc. | Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives |
| NO3175985T3 (enExample) | 2011-07-01 | 2018-04-28 | ||
| UY34171A (es) | 2011-07-01 | 2013-01-31 | Gilead Sciences Inc | Compuestos heterocíclicos fusionados como moduladores del canal iónico |
| WO2013007106A1 (zh) | 2011-07-09 | 2013-01-17 | 广东东阳光药业有限公司 | 作为丙型肝炎病毒抑制剂的螺环化合物 |
| TW201321373A (zh) * | 2011-08-08 | 2013-06-01 | Glaxosmithkline Llc | 化合物 |
| WO2013030750A1 (en) | 2011-09-01 | 2013-03-07 | Lupin Limited | Antiviral compounds |
| KR101991298B1 (ko) | 2011-09-16 | 2019-06-21 | 길리애드 파마셋 엘엘씨 | Hcv 치료 방법 |
| EP3778606A3 (en) | 2011-11-16 | 2021-03-03 | Gilead Pharmasset LLC | Condensed imidazolylimidazoles as antiviral compounds |
| US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
| US9326973B2 (en) | 2012-01-13 | 2016-05-03 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2013118097A1 (en) | 2012-02-10 | 2013-08-15 | Lupin Limited | Antiviral compounds with a dibenzooxaheterocycle moiety |
| US20130309196A1 (en) | 2012-05-16 | 2013-11-21 | Gilead Sciences, Inc. | Antiviral compounds |
| CN103420991B (zh) * | 2012-05-17 | 2017-07-07 | 乳源东阳光药业有限公司 | 作为丙型肝炎抑制剂的吡咯烷衍生物及其在药物中的应用 |
| TWI610916B (zh) | 2012-08-03 | 2018-01-11 | 廣東東陽光藥業有限公司 | 作爲丙型肝炎抑制劑的橋環化合物及其在藥物中的應用 |
| WO2014082380A1 (en) * | 2012-11-29 | 2014-06-05 | Sunshine Lake Pharma Co., Ltd. | Fused ring compounds as hepatitis c virus inhibitors, pharmaceutical compositions and uses thereof |
| CN103848821B (zh) | 2012-11-29 | 2016-10-12 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的螺环化合物、药物组合物及它们的用途 |
| WO2014110687A1 (en) | 2013-01-16 | 2014-07-24 | Merck Sharp & Dohme Corp. | Thiazolyl-substitued tetracyclic compounds and methods of use thereof for treatment of viral diseases |
| HUE047777T2 (hu) | 2013-01-31 | 2020-05-28 | Gilead Pharmasset Llc | Két vírusellenes vegyület kombinációs készítménye |
| RU2507201C1 (ru) | 2013-02-07 | 2014-02-20 | Александр Васильевич Иващенко | Алкил [(s)-1-((s)-2-{5-[4-(4-{2-[(s)-1-((s)-2-метоксикарбониламино-3-метил-бутирил)-пирролидин-2-ил]-3н-имидазол-4-ил}-бута-1,3-диинил)-фенил]-1н-имидазол-2-ил}-пирролидин-1-карбонил)-2-метил-пропил]-карбамат нафталин-1,5-дисульфонат, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний |
| US11484534B2 (en) | 2013-03-14 | 2022-11-01 | Abbvie Inc. | Methods for treating HCV |
| US9717712B2 (en) | 2013-07-02 | 2017-08-01 | Bristol-Myers Squibb Company | Combinations comprising tricyclohexadecahexaene derivatives for use in the treatment of hepatitis C virus |
| US20150023913A1 (en) | 2013-07-02 | 2015-01-22 | Bristol-Myers Squibb Company | Hepatitis C Virus Inhibitors |
| JP2016527232A (ja) | 2013-07-17 | 2016-09-08 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | Ｈｃｖの治療に使用するためのビフェニル誘導体を含む組み合わせ |
| EP4005560A1 (en) | 2013-08-27 | 2022-06-01 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| EP3089757A1 (en) | 2014-01-03 | 2016-11-09 | AbbVie Inc. | Solid antiviral dosage forms |
| CN104803989B (zh) | 2014-01-23 | 2017-12-22 | 广东东阳光药业有限公司 | 作为丙型肝炎抑制剂的桥环化合物及其在药物中的应用 |
| TWI721947B (zh) | 2014-06-11 | 2021-03-21 | 美商基利法瑪席特有限責任公司 | 抗病毒化合物的固態形式 |
| US10617675B2 (en) | 2015-08-06 | 2020-04-14 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| HUE058932T2 (hu) | 2016-04-07 | 2022-09-28 | Glaxosmithkline Ip Dev Ltd | Fehérjemodulátorokként hasznos heterociklikus amidok |
| WO2017181383A1 (en) * | 2016-04-21 | 2017-10-26 | Merck Sharp & Dohme Corp. | Hepatitis c virus inhibitors |
| UA126458C2 (uk) | 2018-02-13 | 2022-10-05 | Гіліад Сайєнсіз, Інк. | Інгібітори pd-1/pd-l1 |
| US10899735B2 (en) | 2018-04-19 | 2021-01-26 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| EP3820572B1 (en) | 2018-07-13 | 2023-08-16 | Gilead Sciences, Inc. | Pd-1/pd-l1 inhibitors |
| AU2019366355B2 (en) | 2018-10-24 | 2022-10-13 | Gilead Sciences, Inc. | PD-1/PD-L1 inhibitors |
| WO2022246072A1 (en) | 2021-05-21 | 2022-11-24 | Gilead Sciences, Inc. | Tetracyclic compounds for the treatment of zika virus infection |
| CN117460734A (zh) | 2021-05-21 | 2024-01-26 | 吉利德科学公司 | 作为寨卡病毒抑制剂的五环衍生物 |
| TN2023000286A1 (en) | 2021-06-14 | 2025-07-02 | Scorpion Therapeutics Inc | Urea derivatives which can be used to treat cancer |
Family Cites Families (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL127610C (enExample) | 1965-06-23 | |||
| CH532608A (de) * | 1969-12-17 | 1973-01-15 | Ciba Geigy Ag | Verfahren zur Herstellung von Bis-aroxazolyl-Verbindungen |
| CH553807A (de) * | 1970-12-23 | 1974-09-13 | Sandoz Ag | Verfahren zur herstellung von dibenzthiophendioxidderivaten. |
| US3808206A (en) | 1971-06-29 | 1974-04-30 | Richardson Merrell Inc | Bis-basic ketones of phenoxathiins and antiviral compositions thereof |
| US4371690A (en) | 1979-07-12 | 1983-02-01 | E. I. Du Pont De Nemours And Company | Heat-resistant rigid polymers from difunctional 9,10-dihydro-9,10-ethanoanthracenes |
| US5288914A (en) | 1984-08-27 | 1994-02-22 | The Dow Chemical Company | Poly(arylcyclobutenes) |
| US5288924A (en) * | 1992-09-18 | 1994-02-22 | Mobil Oil Corporation | Process for starting up an olefin hydration reactor |
| US6054472A (en) | 1996-04-23 | 2000-04-25 | Vertex Pharmaceuticals, Incorporated | Inhibitors of IMPDH enzyme |
| US5807876A (en) | 1996-04-23 | 1998-09-15 | Vertex Pharmaceuticals Incorporated | Inhibitors of IMPDH enzyme |
| CA2252465C (en) | 1996-04-23 | 2007-07-03 | Vertex Pharmaceuticals Incorporated | Urea derivatives as inhibitors of impdh enzyme |
| CA2268391A1 (en) | 1996-10-18 | 1998-04-30 | Vertex Pharmaceuticals Incorporated | Inhibitors of serine proteases, particularly hepatitis c virus ns3 protease |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| WO1998040381A1 (en) | 1997-03-14 | 1998-09-17 | Vertex Pharmaceuticals Incorporated | Inhibitors of impdh enzyme |
| US6010848A (en) | 1997-07-02 | 2000-01-04 | Smithkline Beecham Corporation | Screening methods using an atpase protein from hepatitis C virus |
| IL134233A0 (en) | 1997-08-11 | 2001-04-30 | Boehringer Ingelheim Ca Ltd | Hepatitis c inhibitor peptide analogues |
| CA2338490A1 (en) | 1998-07-27 | 2000-02-10 | Sergio Altamura | Diketoacid-derivatives as inhibitors of polymerases |
| US6323180B1 (en) | 1998-08-10 | 2001-11-27 | Boehringer Ingelheim (Canada) Ltd | Hepatitis C inhibitor tri-peptides |
| EP1128832A4 (en) | 1998-08-21 | 2003-03-05 | Viropharma Inc | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS AND RELATED DISEASES |
| CA2343522A1 (en) | 1998-09-04 | 2000-03-16 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
| WO2000018231A1 (en) | 1998-09-25 | 2000-04-06 | Viropharma Incorporated | Methods for treating or preventing viral infections and associated diseases |
| BR0009167A (pt) | 1999-03-19 | 2001-12-26 | Vertex Pharma | Inibidores de enzima impdh |
| US6242602B1 (en) * | 1999-03-29 | 2001-06-05 | Gentex Corporation | One pot synthesis of 5,10-dihydrophenazine compounds and 5,10-substituted dihydrophenazines |
| US6566365B1 (en) | 1999-11-04 | 2003-05-20 | Biochem Pharma Inc. | Method for the treatment of Flaviviridea viral infection using nucleoside analogues |
| EP1292310A1 (en) | 2000-05-10 | 2003-03-19 | SmithKline Beecham Corporation | Novel anti-infectives |
| US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
| SV2003000617A (es) | 2000-08-31 | 2003-01-13 | Lilly Co Eli | Inhibidores de la proteasa peptidomimetica ref. x-14912m |
| EP1256628A3 (en) | 2001-05-10 | 2003-03-19 | Agouron Pharmaceuticals, Inc. | Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof |
| EP1401825B1 (en) | 2001-06-11 | 2009-08-05 | Virochem Pharma Inc. | Thiophene derivatives as antiviral agents for flavivirus infection |
| WO2002100846A1 (en) | 2001-06-11 | 2002-12-19 | Shire Biochem Inc. | Compounds and methods for the treatment or prevention of flavivirus infections |
| AR035543A1 (es) * | 2001-06-26 | 2004-06-16 | Japan Tobacco Inc | Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con |
| JP2003212846A (ja) * | 2001-06-26 | 2003-07-30 | Japan Tobacco Inc | 縮合環化合物及びｃ型肝炎治療剤 |
| JP4558314B2 (ja) | 2001-07-20 | 2010-10-06 | ベーリンガー インゲルハイム （カナダ） リミテッド | ウイルスポリメラーゼインヒビター |
| UA101465C2 (ru) * | 2001-07-25 | 2013-04-10 | Бёрингер Ингельхайм (Канада) Лтд. | Использование индольного соединения для лечения или предупреждения инфицирования вирусом гепатита с |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| JP2005515172A (ja) | 2001-11-02 | 2005-05-26 | グラクソ グループ リミテッド | Ｈｃｖ阻害剤としての４−（６−員）−ヘテロアリールアシルピロリジン誘導体 |
| WO2003037894A1 (en) | 2001-11-02 | 2003-05-08 | Glaxo Group Limited | 4-(5-membered)-heteroaryl acyl pyrrolidine derivatives as hcv inhibitors |
| JP2005511572A (ja) | 2001-11-02 | 2005-04-28 | グラクソ グループ リミテッド | Ｈｃｖ阻害剤としてのアシルジヒドロピロール誘導体 |
| EA012410B1 (ru) | 2004-01-30 | 2009-10-30 | Медивир Аб | Ингибиторы серин-протеазы ns-3 hcv |
| WO2006039356A2 (en) | 2004-09-29 | 2006-04-13 | Cytovia, Inc. | Substituted n-aryl-9-oxo-9h-fluorene-1-carboxamides and analogs as activators of caspases and inducers of apoptosis |
| US7355199B2 (en) * | 2004-11-02 | 2008-04-08 | E.I. Du Pont De Nemours And Company | Substituted anthracenes and electronic devices containing the substituted anthracenes |
| DE102005022020A1 (de) | 2005-05-12 | 2006-11-23 | Merckle Gmbh | Dibenzocycloheptanverbindungen und pharmazeutische Mittel, welche diese Verbindungen enthalten |
| US8143288B2 (en) | 2005-06-06 | 2012-03-27 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US8329159B2 (en) * | 2006-08-11 | 2012-12-11 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7759495B2 (en) * | 2006-08-11 | 2010-07-20 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7745636B2 (en) | 2006-08-11 | 2010-06-29 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7659270B2 (en) * | 2006-08-11 | 2010-02-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7741347B2 (en) * | 2007-05-17 | 2010-06-22 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US7728027B2 (en) * | 2007-08-08 | 2010-06-01 | Bristol-Myers Squibb Company | Process for synthesizing compounds useful for treating hepatitis C |
| US8629171B2 (en) * | 2007-08-08 | 2014-01-14 | Bristol-Myers Squibb Company | Crystalline form of methyl ((1S)-1-((25)-2-(5-(4'-(2-((25)-1((2S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-2-pyrrolidinyl)-1H-imidazol-2-yl)-1-pyrrolidinyl)carbonyl)-2-methylpropyl)carbamate dihydrochloride salt |
| US7704992B2 (en) * | 2008-02-13 | 2010-04-27 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| JP5266786B2 (ja) * | 2008-02-20 | 2013-08-21 | 富士ゼロックス株式会社 | 新規なフェノチアジン化合物 |
| WO2010096462A1 (en) * | 2009-02-17 | 2010-08-26 | Enanta Pharmaceuticals, Inc | Linked diimidazole derivatives |
| SG174883A1 (en) | 2009-03-27 | 2011-11-28 | Presidio Pharmaceuticals Inc | Fused ring inhibitors of hepatitis c |
-
2010
- 2010-03-25 SG SG2011067683A patent/SG174883A1/en unknown
- 2010-03-25 JP JP2012502264A patent/JP5735482B2/ja not_active Expired - Fee Related
- 2010-03-25 US US13/260,378 patent/US9150554B2/en not_active Expired - Fee Related
- 2010-03-25 EP EP10756872A patent/EP2410843A4/en not_active Withdrawn
- 2010-03-25 MX MX2011010132A patent/MX2011010132A/es active IP Right Grant
- 2010-03-25 EA EA201190224A patent/EA201190224A1/ru unknown
- 2010-03-25 WO PCT/US2010/028730 patent/WO2010111534A1/en not_active Ceased
- 2010-03-25 AU AU2010229795A patent/AU2010229795A1/en not_active Abandoned
- 2010-03-25 BR BRPI1012282A patent/BRPI1012282A2/pt not_active IP Right Cessation
- 2010-03-25 KR KR1020117025221A patent/KR20110131312A/ko not_active Withdrawn
- 2010-03-25 CA CA2755658A patent/CA2755658A1/en not_active Abandoned
- 2010-03-25 CN CN201080021446.2A patent/CN102427726B/zh not_active Expired - Fee Related
- 2010-03-25 PE PE2011001719A patent/PE20120773A1/es not_active Application Discontinuation
- 2010-03-26 TW TW099109325A patent/TW201038560A/zh unknown
- 2010-03-29 AR ARP100101000A patent/AR076164A1/es unknown
-
2011
- 2011-09-18 IL IL215202A patent/IL215202A0/en unknown
- 2011-09-26 CL CL2011002377A patent/CL2011002377A1/es unknown
- 2011-10-24 ZA ZA2011/07753A patent/ZA201107753B/en unknown
- 2011-10-27 CO CO11145231A patent/CO6450600A2/es active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2755658A1 (en) | 2010-09-30 |
| KR20110131312A (ko) | 2011-12-06 |
| AU2010229795A1 (en) | 2011-10-13 |
| US9150554B2 (en) | 2015-10-06 |
| IL215202A0 (en) | 2011-12-29 |
| JP5735482B2 (ja) | 2015-06-17 |
| MX2011010132A (es) | 2011-10-14 |
| PE20120773A1 (es) | 2012-07-19 |
| EA201190224A1 (ru) | 2012-03-30 |
| CL2011002377A1 (es) | 2012-01-20 |
| WO2010111534A1 (en) | 2010-09-30 |
| SG174883A1 (en) | 2011-11-28 |
| US20120040962A1 (en) | 2012-02-16 |
| CN102427726B (zh) | 2014-10-08 |
| ZA201107753B (en) | 2012-07-25 |
| CO6450600A2 (es) | 2012-05-31 |
| AR076164A1 (es) | 2011-05-26 |
| EP2410843A4 (en) | 2012-08-08 |
| CN102427726A (zh) | 2012-04-25 |
| TW201038560A (en) | 2010-11-01 |
| JP2012522003A (ja) | 2012-09-20 |
| EP2410843A1 (en) | 2012-02-01 |
| HK1166446A1 (en) | 2012-11-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI1012282A2 (pt) | inibidores de anel fundidos da hepatite c. | |
| BRPI1013342A2 (pt) | conjunto de anel de turbina. | |
| BRPI1007968A2 (pt) | derivado de anel hetero | |
| BRPI1012012A2 (pt) | anel de desvio de corrente | |
| BRPI1014714A2 (pt) | conjuntos de fixação expansíveis. | |
| BRPI1008684A2 (pt) | queimador de gás. | |
| BRPI0813808A2 (pt) | Anel de segmento | |
| BRPI1007836A2 (pt) | Inibidores do vírus c da hepatite | |
| BRPI1008846A2 (pt) | inibidores do vírus da hepatite c | |
| BRPI1013393A2 (pt) | inibidores do vírus da hepatite c | |
| BRPI1014084A2 (pt) | inibidores do vírus da hepatite c | |
| BRPI1014956A2 (pt) | agentes antinflamatórios. | |
| BRPI1010301A2 (pt) | composição. | |
| BRPI1008949A2 (pt) | Cetoenóis haloalquilmetilenóxi-fenil-substituídos. | |
| BRPI1010620A2 (pt) | métodos de conjugação | |
| BR112012004296A2 (pt) | anel calibrador expansível. | |
| BRPI1008782A2 (pt) | primidinas fundidas | |
| BRPI1011134A2 (pt) | turbomáquina. | |
| IT1398793B1 (it) | Motociclo. | |
| BRPI1016117A8 (pt) | derivados de isoxazol-isoxazol e isoxazol-isotiazol. | |
| EP2399914A4 (en) | FUSED HETEROCYCLIC CORE COMPOUND | |
| BR112012000281A2 (pt) | proteína quimérica. | |
| FR2947376B1 (fr) | Sectionneur. | |
| IT1396487B1 (it) | Convogliatore. | |
| BRPI1016192A2 (pt) | derivados de soxazol. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |